Member Info for Krone

It’s an ill wind....
https://endpts.com/pfizers-xeljanz-flunks-its-post-marketing-safety-study-renewing-harsh-questions-for-jak-class/

If Tim is presenting additional material we can expect a further RNS today.....

Slipping timelines?
es

The bulk of Sareum’s value rests on the late preclinical autoimmune therapy SDC-1801, with planned filing to start clinical development in H121 followed by possible exploratory clinical studies, if funding allows, from H221. This could open the way to a substantive partnering deal from Q222. Partnering could be helped if the related BMS therapeutic deucravacitinib gains FDA approval and blockbuster sales in psoriasis. Sareum could offer a partner a promising route to an autoimmune therapy with potentially broad indications.

$SAR #Sareum Holdings PLC Sareum Holdings - Starting to tick the right boxes: The bulk of Sareum’s value rests on the late preclinical autoimmune therapy SDC-1801, with planned filing to start clinical development in H121 followed by… dlvr.it/RrJkXp #equity #stocks
https://twitter.com/researchpool/status/1353740933758500864?s=21

Hi Working - Apols, I was thinking of Momly which has FDA fast track status. Given however that SRA737 has been shown to be efficacious in anogenital, an area of significant unmet need with few current treatment options, it would seem reasonable to expect 737 to be granted fast track also.
Just as a reminder http://www.sareum.com/news/press-releases-and-news/2019/sierra-seeks-strategic-options-sra737/
Also noted in the IMC notes to the December conference call it was confirmed that 'We do have some contact with Sierra's senior management. '. Reasonable to assume that Tim's confidence in the 'timely' progression will be based in part at least on discussions with Dilly and 6th Element......

But wasn’t SRA737 marked for fast track, given that it showing efficacy in areas of unmet clinical need.

"In a timely manner" is an idiom. If something is finished quickly, on time, or without wasting any time, then it has been done "in a timely manner".

We also recognise that the recently amended deal between Sierra and CPF on SRA737 is a key step in restarting the clinical advancement of this promising asset....... we are confident that this amendment will expedite the SRA737 programme advancing in a more timely manner.

Belhus....if you mean the trademark applications, your guess is as good as mine.

‘Currently there is no direct evidence of superiority regarding the efficacy or safety of one JAKI over another one’ ..... incorrect in respect of Sareum’s SDC1801/2 which have no identified toxicity issues!

The CSF has released a new poster summarising points to consider for the treatment of patients with immune mediated inflammatory diseases with JAK inhibitors. Click here to download it for free.

As coronavirus variants trigger new alarms, the NIH is putting an under-the-radar ‘next-gen’ vaccine into PhI
John Carroll
Editor & Founder
Over the past year, the world has been transfixed by the development of new vaccines to fight SARS-CoV-2. In a frenzy of activity, the new mRNA approach has delivered pioneering emergency approvals in record time. And with some setbacks, the more traditional big players are coming along with added jabs as the most affluent nations in the world begin to vaccinate large portions of their populations.

But what about these new threats that have come along, with variants in the US and South Africa raising fears that the virus will mutate into new forms that can escape these vaccines? Where are the next-gen coronavirus vaccines coming from?

Gritstone Oncology $GRTS, a somewhat bruised but determinedly unbowed oncology player which has had its ups and downs over the years, thinks they may have the answer with a new vaccine that promises to simultaneously flag the spike targeted by the first-gen jabs as well as induce T cell immunity. And they’ve gathered support for this doubled-edged viral sword from the Gates Foundation, advancing a new vaccine that’s about to go into Phase I trials at NIAID.....
https://e.endpointsnews.com/t/t-l-mlrqhk-bkylturlh-k/

Interesting to note that Stephen Parker has retweeted regarding the Kymab deal!
https://twitter.com/drmartinturner/status/1348897429647712256?s=21

https://www.fiercepharma.com/pharma/jpm-gilead-s-veklury-now-used-half-hospitalized-u-s-covid-patients-delivers-big-revenue-bump
https://www.bmj.com/content/371/bmj.m4457

BoilB - thanks for the reminder and let’s not forget SRA737 https://www.researchgate.net/publication/335441380_Combination_treatment_of_the_oral_CHK1_inhibitor_SRA737_and_low_dose_gemcitabine_enhances_the_effect_of_PD-L1_blockade_by_modulating_the_immune_microenvironment_in_small_cell_lung_cancer
https://www.pharmiweb.com/press-release/2020-03-12/sareum-notes-publication-of-new-research-highlighting-the-therapeutic-potential-of-sra737-in-a-new-drug-combination-targeting-lung-and-colorectal-canc

China Showcase - High profile opportunity for an Aurora FLT3 announcement?
https://informaconnect.com/biotech-showcase/agenda/2/

Arguably a significant takeaway from the IMC AGM question responses was confirmation that "We do have some contact with Sierra's senior management". If this is the case then Tim's comments "we are confident that this amendment will expedite the advancement of the SRA737 programme in a timely manner" would appear to be robust. Just depends on the definition of timely manner.

Many thanks Thoth to you and all serious contributors.

https://twitter.com/robindavison2/status/1344676244441485316?s=21
Roll on 2021!

Hi Mrred
Section 4 here refers: https://www.sec.gov/Archives/edgar/data/1290149/000119312516765907/d255357dex101.htm

https://www.theguardian.com/world/2020/dec/27/the-breakthough-medicines-that-could-change-the-course-of-covid?CMP=Share_iOSApp_Other